TEL AVIV, Israel, May 04, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
| Conference Call & Webcast | ||
| Monday, May 16, 2016 @ 8:30am Eastern Time | ||
| Domestic: | 855-469-0611 | |
| International: | 484-756-4341 | |
| Passcode: | 97907530 | |
| Webcast: | http://www.alcobra-pharma.com/events.cfm | |
| Replays available through May 30, 2016 | ||
| Domestic: | 855-859-2056 | |
| International: | 404-537-3406 | |
| Passcode: | 97907530 | |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.